Compliance
This section focuses on health care compliance and regulations – both national and state – including the ACA. It includes changes in health care law, regulation, and court decisions and their impact on health insurance professionals, employers, and individuals.
Prices rose faster than inflation for 22% of top generic drugs reviewed between 2005 and 2014, according to a report released Thursday by HHS' Office of Inspector General.
A newly qualified November 2016 ballot measure would impose price controls on state drug purchases, potentially setting up an expensive battle with the pharmaceutical industry.
Kaiser Permanente is preparing to instill its integrated model for high-quality care at sustainable costs in the minds of future physicians. The Oakland, Calif.-based system plans to open an independent medical school in Southern California, with its first class expected to enroll in fall 2019.
In another sign that a 2014 truce is in danger, a powerful union for health care workers has launched a $3 million fund that could fund a new ballot battle with hospitals.
President Obama on Friday signed a spending package with several health care-related provisions, including some that affect the Affordable Care Act, the Los Angeles Times reports.
Martin Shkreli, a boastful pharmaceutical executive who came under withering criticism for price gouging vital drugs, denied securities fraud charges on Thursday following an early morning arrest, and was freed on a $5 million bond.
As part of his push for the Affordable Care Act in 2009, President Obama came to Central High School to laud this community as a model of better, cheaper health care.
In the eyes of Martin Weil, it’s not the hard slog of political deal-making that explains why his 26-year old daughter, a quadriplegic with cerebral palsy who is unable to speak, struggles to keep the services she needs.
The penalty for failing to have health insurance is going up, perhaps even higher than you expected.
Martin Shkreli is once again provoking alarm with a plan to sharply increase the price of a decades-old drug for a serious infectious disease. This time the drug treats Chagas disease, a parasitic infection that can cause potentially lethal heart problems.